The combination of CA19-9 normalization and metabolic tumor volume change predicts long-term survival for resectable and borderline resectable pancreatic cancer patients receiving preoperative chemoradiotherapy; the result of multicenter trial.

The combination of CA19-9 normalization and metabolic tumor volume change predicts long-term survival for resectable and borderline resectable pancreatic cancer patients receiving preoperative chemoradiotherapy; the result of multicenter trial. - The combination of CA19-9 and PET for the assessment of PC patients with NACRT

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037142

Enrollment

120

Registered

2019-06-24

Start date

2019-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pnacreatic cancer patients who underwent radical surgery after neoadjuvant chemoradiotherapy.

Exclusion criteria

Exclusion criteria: 1, Patients under 20 years old 2, In cases that CA19-9 and FDG-PET was not performed both before and after chemoradiotherapy. 3, In cases that the value of CA19-9 was within normal limits before the initiation of neoadjuvant chemotherapy. 4, In cases that the value of SUV-max before neoadjuvant chemoradiotherapy was under 2.0.

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Disease free survival Pathological effect Pathological staging	—

Countries

Japan

Contacts

Public ContactAkita Hirofumi

Osaka University Graduate School of Medicine Department of Gastoroenterological Surgery

hakita@gesurg.med.osaka-u.ac.jp0668793251

Outcome results